North America RNAi Therapeutics Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America RNAi Therapeutics Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America RNAi Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America RNAi Therapeutics Market Regional Analysis

6.2 North America RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)

6.3 North America RNAi Therapeutics Market Forecast Analysis

7. North America RNAi Therapeutics Market Analysis – by Molecule Type

7.1 Small Interfering RNAs

7.1.1 Overview
7.1.2 Small Interfering RNAs: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 MicroRNA

7.2.1 Overview
7.2.2 MicroRNA: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. North America RNAi Therapeutics Market Analysis – by Application

8.1 Genetic Disorders

8.1.1 Overview
8.1.2 Genetic Disorders: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Oncology

8.2.1 Overview
8.2.2 Oncology: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.3 Neurodegenerative Disorders

8.3.1 Overview
8.3.2 Neurodegenerative Disorders: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.4 Cardiovascular

8.4.1 Overview
8.4.2 Cardiovascular: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.5 Respiratory Disorders

8.5.1 Overview
8.5.2 Respiratory Disorders: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.6 Infectious Diseases

8.6.1 Overview
8.6.2 Infectious Diseases: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.7 Renal Diseases

8.7.1 Overview
8.7.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. North America RNAi Therapeutics Market Analysis – by Route of Administration

9.1 Intradermal Injections

9.1.1 Overview
9.1.2 Intradermal Injections: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.2 Pulmonary Delivery

9.2.1 Overview
9.2.2 Pulmonary Delivery: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.3 Intravenous Injections

9.3.1 Overview
9.3.2 Intravenous Injections: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.4 Intraperitoneal Injections

9.4.1 Overview
9.4.2 Intraperitoneal Injections: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. North America RNAi Therapeutics Market Analysis – by End User

10.1 Diagnostic Laboratories

10.1.1 Overview
10.1.2 Diagnostic Laboratories: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10.2 Research and Academic Laboratories

10.2.1 Overview
10.2.2 Research and Academic Laboratories: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10.3 Hospitals

10.3.1 Overview
10.3.2 Hospitals: North America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

11. North America RNAi Therapeutics Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
11.2.1.1 North America RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.1.1 US: North America RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.1.2 US: North America RNAi Therapeutics Market Breakdown, by Application
11.2.1.1.3 US: North America RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.1.4 US: North America RNAi Therapeutics Market Breakdown, by End User

11.2.1.2 Canada: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.2.1 Canada: North America RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.2.2 Canada: North America RNAi Therapeutics Market Breakdown, by Application
11.2.1.2.3 Canada: North America RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.2.4 Canada: North America RNAi Therapeutics Market Breakdown, by End User

11.2.1.3 Mexico : North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.3.1 Mexico : North America RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.3.2 Mexico : North America RNAi Therapeutics Market Breakdown, by Application
11.2.1.3.3 Mexico : North America RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.3.4 Mexico : North America RNAi Therapeutics Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Alnylam Pharmaceuticals, Inc

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Arrowhead Pharmaceuticals, Inc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Quark

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Rexahn Pharmaceuticals, Inc

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Arbutus Biopharma

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America RNAi Therapeutics Market